Bounce Mobile Systems Inc (BNCM)

[Humbert]

Probably a MM, yes.

[sissyjane1]

I just a simple kinda person ..explain why there is a dump every day at closing dragging the pps down ?? .....MM ??

[sissyjane1]

I have tried to rationalize why people dont have a reasonable interest in this ticker , it has all the factors you could ask for in a company that will succeed , Delex shows a profit from operations , unlike the majority of otc stocks and many other big boy stocks. Its been in business for over 15 years , ranked 3 rd against its competition, has expansion plans to increase revs,has FDA products to sell, has new contracts with other countries , getting ready to uplist and will possibility end up on the nasdaq exchange. Here is the kicker, what an opportunity to get in at .01 unlike peeps who spend thousands on otc stocks that are just born losers and they even know they are. I looked at a ticker the other day which is a shell has not made a penny , for years , has no operations , no business , but has a PPS of .34 ????
(TGLO), after the great 24 10K report not even a fraction of a bump in PPS , in fact a decrease was realized, its all most like Delex does not exist ...just hard to grasp the reality of the situation......we will see.

[sissyjane1]

TYC...YET

[ToucanYoucan]

$BNCM - Nobody follows this stock. This board has 85 followers and that number has not changed in weeks. Personally, I don't want anyone to follow it.

[sissyjane1]

EOD sells .0093 ??

[Tradingguru06]

$BNCM looks like some good pow wow & news coming down the pipeline shortly on this company! . Great entry point before the Easter break! GLTA!!

[Penny Stocks 2.0]

Strategic partnerships alert! $BNCM's DELEX is teaming up with global medical device leaders like Amsino, Masimo, and Verathon to revolutionize healthcare solutions. #MedicalInnovation #BNCM
Verathon generates $125 million in Revenue 
Amsino generates $540 million Revenue 
Masimo generates $2.05 Billion in Revenue 
Sleeping with a few more giants of the Industry 

[Humbert]

Once this moves up to QB, it'll trade in the .05 - .10 range, very easily

[Penny Stocks 2.0]

The merger was only completed October of 2024. The 2025 revenue and profit will far exceed 2024. 

[sissyjane1]

PS 2.0...I dont understand what you mean by 12 trailing months , the annual report was for the year ending 2024 ? If I remember correctly Delex sales thru 9/24 was around 9 mil per PR unaudited

[sissyjane1]

mods......post by Penny Stocks 2.0 needs to be stickied ...post 4184 BUYING/HOLDING $BNCM long term

[Penny Stocks 2.0]

BUYING/HOLDING $BNCM long term
Why? Multi Dollars coming

Most Undervalued Pharmaceutical stock with over 30 FDA Approved Products, sold in more than 900 Pharmacies and Hospitals, 160 Drug Chains and 380 dispensing Medical Doctors and clinics.

Expand to 60 Pharmacies Nationwide

Uplist to the OTCQB and Ultimately the Nasdaq

DELEX Pharma International, Inc. is the of DLX Holdings, Inc. and recently acquired JMN Brother's Pharma Limited, Inc.

Audited Financials by SyCip Gorres Velayo & Co, a Subsidiary of Ernst and Young Global @EY_US

Assets $10.5 million
Liabilities $8.8 million
Revenue $10.25 million
Net Profit $159,000

Does not include 12 Trailing Months. Merger closed October 24th, 2025
Expect $20m to $30m over 12 months.

BNCM and DELEX has identified several targets across the AI diagnostics, telehealth, and medical device segments, with negotiations underway.

BNCM and DELEX is actively structuring strategic partnerships with regional clinics and hospital groups.

DELEX Pharma is an ISO 9001:2015-certified, ranked 3rd largest national company according to IQVIA.

Announcement of Name Change and Ticker Symbol

Application to rename BNCM to DELEX and update the ticker symbol is PENDING
DELEX amplified alliances with leading international medical device companies such as Amsino, Masimo, and Verathon in the U.S., as well as SternMed GmbH in Germany.

One of the prominent anesthesia products of DELEX, penetrating 90% of the hospitals across the country, is IFIMOL, a premier brand of paracetamol. In 2018, IFIMOL was included in the IQVIA Report as one of the Top 200 Hospital Ethical Products. Another notable product is INTRAFEN, the pioneering and sole Ibuprofen brand in I.V. preparation introduced in the Philippines in August 2018.

DELEX launched five products to provide effective solutions: IFOSFAMIDE (Fosfalex), FLUOROURACIL (Flouracilex), PACLITAXEL (Paclitex), DOXORUBICIN (D-xobin), and DOCETAXEL (Docelex).
4 Antibacterial products are being offered by DELEX in the Philippine market which are all premium, affordable, and widely-used brands in ICUs. These anti-infective brands are DELEXIGYL (Metronidazole), CEFTREX (Ceftriaxone), CEFTAZIN (Ceftazidime), and AXAZOLID (Linezolid). In addition to anti-infective products, DELEX also offers FUNGINIL, an antifungal product that is the first branded generic Fluconazole available in the Philippines.

Critical Care Products include HUMAL, a blood substitute and plasma protein fraction solution manufactured by Fortune Global 500 company in India, and TOTILAC, which is the only premixed hypertonic lactate solution in three percent (3%) preparation available in the local market. The company also markets DOBULEX and NOREPIN, which had been the leading generic Dobutamine and norepinephrine solutions in the country. Lastly, Nicardilex, a new product in the market offered by DELEX, immediately became the second-leading Nicardipine brand due to its affordability.

PARTNERS 
ARGENTINA – Laboratorio Kemex SAUSA – Verathon, Amsino, ICU Medical Inc. 
FRANCE – CAIR LGL
GREECE – Anfarm Hellas S.AINDIA – AXA Parenterals Ltd., United Biotech Ltd., CSP Lifesciences, Rusan Pharma
INDONESIA - Glorious Dexa Mandaya Inc.
NETHERLANDS – Philips Healthcare
SINGAPORE – Innokeys Pte. Ltd., Kalbe International Pte., Ltd.
SWITZERLAND – Sandoz (Novartis)
TURKEY – Biem Ilac Sanayi ve Ticaret A.S., Farma-Tek Ilac Sanayi Ticaret A.S
UNITED KINGDOM – Smiths Medical Ltd./ICU MEDICAL INC)

MANUFACTURER'S
AHN-GOOK PHARMACEUTICAL CO., LTD.
AXA PARENTERALSBIRGI MEFAR
MYUNGMOON PHARM. CO., LTD
NEON LABORATORIES
PT. FINULSOLPRIMA FARMA INTERNATIONAL
RELIANCE LIFE SCIENCES
STALLION LABORATORIES
UNIQUE PHARMACEUTICAL LABORATORIES
UNITED BIOTECH, INDIA

delexhealth.com
bncm.net

#Investors #Wallstreet #Investment #StocksToBuy#StockMarket #StockAlert #Nasdaq @Nasdaq #Nyse @NYSE$NVDA $TSLA $AMC $IQST $DJT $PLUG $ILLR $FNMA $RSPI $SPZI $ABIT $IONQ $GME $GTVH $FITY $TWOH

[threewheeler]

BNCM yesterday 400k T-Trade today only 50K T-Trade maybe we at the end of these

[ToucanYoucan]

$BNCM - I don't mind the pps where it is now, I just keep adding.

[sissyjane1]

In fact we did nt get even a slight bump from the fins even with all the fantastic news about BNCM..just the reverse !!!!!

[threewheeler]

so we just need to announce are next location to open will be on Space X , LMAO

[Humbert]

Yeah, it's really gross how people buy into fake stories while real companies like BNCM languish.

[sissyjane1]

There are otc stocks that have actually no products, no revenues and millions in losses and still trade volumes in the millions daily and BNCM with everything postive going for them cant get off .01, really strange , guess good things happen for those who wait ...Maybe ???

[sissyjane1]

wish we had a more positive PPS reaction to financials, this ticker is just begging to run !!

[Penny Stocks 2.0]

$BNCM My favorite Recent News worth $$$'s...#FDA APPROVAL 
DELEX Critical Care Products Approved by Philippines FDA
Reno, Nevada, United States, 3rd Oct 2024 - DELEX Pharma offers a wide range of Critical Care products approved by the Philippines' Food and Drug Administration (FDA). ICU (Intensive Care Unit) is a critical environment for patients facing severe health challenges.

DELEX Critical Care Products
The Critical Care products are part of DELEX Pharma's broader portfolio designed to address gaps in the availability of specialized critical care drugs. It is very essential for addressing a wide array of critical care needs, from managing severe pain and hypertension to supporting cardiac function and blood pressure. 
These products are manufactured under strict compliance with FDA standards, ensuring their quality and effectiveness in critical care management. Details or specific inquiries about these products is available at DELEX Pharma website. 
DELEX's Critical Care Product Distribution
The critical care products are strategically placed in drugstore chains nationwide to enhance accessibility. One of the key distribution channels is Mercury Drug, the largest pharmacy chain in the country with thousands of branches, including those in remote areas. This extensive network significantly increases market reach and drives sales growth for the organizations critical care products.

DELEX Critical Care Product Registrations with the FDA 
1.) Name of Product : GLISENIT (Nitroglycerin)Purpose of Product : Provides relief from anginal chest pain through vasodilation
FDA Registration Number : DRP-13372
Learn MoreLive in 215 hours?
https://verification.fda.gov.ph/ALL_DrugProductslist.php?cmd=search&t=ALL_DrugProducts&psearch=DRP-13372&psearchtype=
2.) Name of Product : BETALEX (Labetalol)Purpose of Product : Treats severe hypertension, including hypertensive disorders in pregnancy
FDA Registration Number : DR-XY48744
https://verification.fda.gov.ph/ALL_DrugProductslist.php?cmd=search&t=ALL_DrugProducts&psearch=DR-XY48744.+&psearchtype=
You May Like
Bill Gates Said It's A 'Gross Oversimplification' To Compare Elon Musk To 'Genius' Steve Jobs — 'You Wouldn't Walk Into A Room And Confuse Them'
Benzinga
Kevin O'Leary Says Trump Will 'Never Change'—Claims People Will Quickly Forget This Period When They See The Opportunity Ahead
Benzinga
Xi Jinping Steering Clear Of Trump Negotiations To Avoid Political Backlash At Home, Says Expert: China 'Doesn't Have Any Cards In This' Game
Benzinga
Mark Cuban Says, If They Replaced Elon Musk With Him, He'll Still Try to Make Government Smaller By 'Cutting A Lot Of People'
Benzinga
'Liberation Day' Tariffs? Why Some Americans Are Rushing To Buy A Car Before Trump's 25% Auto Duty Hits
Benzinga
by Taboola
3.) Name of Product : AXALINE 3% (Sodium Chloride)Purpose of Product : Used in the management of severe sodium chloride depletion when electrolyte restoration is required in following cases like low salt syndrome and hyponatremia
FDA Registration Number : DR-XY48414
https://verification.fda.gov.ph/ALL_DrugProductslist.php?cmd=search&t=ALL_DrugProducts&psearch=DR-XY48414&psearchtype=
4.) Name of Product : DOBULEX (Dobutamine)Purpose of Product : he product is the first-choice inotrope for patients with measured or suspected low cardiac output
FDA Registration Number : DR- XY38709
https://verification.fda.gov.ph/ALL_DrugProductslist.php?cmd=search&t=ALL_DrugProducts&psearch=DR-+XY38709&psearchtype=
5.) Name of Product : TOTILAC (Hypertonic Lactate)Purpose of Product : Treatment for a prolonged decrease in intracranial pressure during acute episodes of intracranial hypertension, including Traumatic Brain Injury (TBI)
FDA Registration Number : DR-XY33427
https://verification.fda.gov.ph/drug_productslist.php?cmd=search&t=drug_products&psearch=DR-XY33427&psearchtype=
6.) Name of Product : NOREPIN (Norepinephrine)Purpose of Product : The first-line vasopressor for hypotension due to shock
FDA Registration Number : DR-XY38818
https://verification.fda.gov.ph/ALL_DrugProductslist.php?cmd=search&t=ALL_DrugProducts&psearch=DR-XY38818&psearchtype=
7.) Name of Product : NICARDILEX (Nicardipine Hydrochloride)Purpose of Product : Recommended drug for the treatment of hypertensive crisis, eclampsia, and : perioperative hypertension
FDA Registration Number : DRP-6940
https://verification.fda.gov.ph/ALL_DrugProductslist.php?cmd=search&t=ALL_DrugProducts&psearch=DRP-6940&psearchtype=
 

[Tradingguru06]

me too. Hopefully there's a good news

[Humbert]

Expecting some nice updates here, followed by the uplisting process

[Hitman970]

After the RS?

[Humbert]

Uplist is coming

[Penny Stocks 2.0]

I expect lots of game changing news. 

[threewheeler]

BNCM load em its all coming together
Bounce Mobile Systems BNCM
@BNCMotc
·
44m
$BNCM utilizing the short holiday week to prepare extended & substantial material events filings & press release re new & completed business developments

[Penny Stocks 2.0]

Big Tweet »»$BNCM utilizing the short holiday week to prepare extended & substantial materual events filings & press release re new & completed business developments

$BNCM utilizing the short holiday week to prepare extended & substantial materual events filings & press release re new & completed business developments

— Bounce Mobile Systems BNCM (@BNCMotc) April 14, 2025

[sissyjane1]

really what is needed is UPLISTING asap

[sissyjane1]

Humbert ...now what we need are some buyers....a lot of buyers

[sissyjane1]

most otc companies show losses yearly , Delex has shown profits for 2 years , a lot of the revenues have been spent
on expansion and inventory for new business which will be profitable in future revenues, its a win win situation for 2025 a lot of activity going to happen in 25. It shows how strong Delex is and will be. To run a business pay all expenses ,dividends , spend the majority of revenue for expansion and product and be a rep for imagining equipment (Phillips) for hospitals , have new contracts with , it all looks positiveother countries and being active in medical conferences thru 11/25

[Humbert]

Over $10,000,000 revenue and a float of ~40,000,000, licensed to sell essential drugs in a rapidly expanding market. I'm buying as much as I can under .02

[sissyjane1]

after the news and fin statements it is finally becoming very clear the future for Delex will be very positive and prosperous.

[Humbert]

It's becoming clear that BNCM will be one of the best OTC stocks of 2025, if not THE best performing OTC stock. Those who load here could make millions. The story is unbeatable.

[threewheeler]

https://www.otcmarkets.com/otcapi/company/financial-report/454379/content

[threewheeler]

Bounce Mobile Systems, Inc. (OTC: BNCM) Supplemental Filing
Company Provides Strategic 2025 Forward Guidance & Outlook post-Merger with
DELEX Healthcare Group
April 2025 — Bounce Mobile Systems, Inc. (OTC: BNCM) (“BNCM” or the “Company”) is
pleased to provide shareholders with a comprehensive supplemental OTC MARKETS
filing update on its 2025 outlook, continuing the momentum set forth in its successful 2024
merger with DELEX Healthcare Group, Inc., and reinforcing its strategic evolution into a
fully integrated healthcare innovation company.
As outlined in our previously published PR updates, BNCM’s transition into the healthcare
sector under the leadership of the DELEX Group has marked a transformative era for the
Company. This transition has brought forward a dynamic management structure, access
to proprietary technologies, and an ambitious roadmap to position BNCM as a disruptive
player in the healthcare innovation ecosystem.
2024 Milestones Recap
1. Strategic Merger with DELEX Healthcare Group, Inc.
This merger laid the foundation for the Company’s pivot into advanced healthcare solutions,
leveraging DELEX’s operational infrastructure, industry expertise, and growing network of
healthcare assets.
2. Management and Control Shift to DELEX Group
As announced in Q1 2024, the shift in control to DELEX brought in a highly experienced
executive team with a proven record in scaling healthcare ventures, enhancing corporate
governance, and driving shareholder value.
3. Roadmap Unveiled for Innovation and Market Penetration
BNCM and DELEX introduced a multi-phase plan to integrate digital health technologies,
expand service offerings, and establish a footprint in emerging medical markets.
4. Operational Realignment and Asset Optimization
Throughout 2024, BNCM and DELEX is focused on consolidating its legacy operations,
reallocating resources toward scalable healthcare initiatives, and exploring synergistic
acquisitions within the health-tech space.
2025 Strategic Outlook and Forward Plans
Looking ahead, BNCM and DELEX is fully committed to accelerating the deployment of
innovative healthcare solutions and expanding its market reach through:
1. Delivering Continued Growth
DELEX has posted strong growth for the past 15 years and now has over 200 staffs, 30
Products approved by the Philippines FDA, supplies to over 900 pharmacies and hospitals,
160 drug chains and over 380 dispensing medical doctors and clinics.
DELEX will continue to develop in-demand high quality products, secure more innovative
medical technologies, expand its distribution channels, formed strategic partnerships
across the region, increase its pharmacy stores from 3 to 60 and actively participate in
medical conventions and exhibitions.
2. Delivering Innovative and Cutting-Edge Medical Technologies
DELEX has introduced various advanced technologies, starting with the CADD-Solis
infusion systems from Smiths Medical, Ultrasound for Cardiology from Philips, Neutraclear
needleless connectors from CAIR LGL. Anesthesia Unit, Electrosurgical Unit, Surgical light,
and Surgical table from SternMed GmbH.
3. International Expansion Strategy
BNCM and DELEX are jointly evaluating entry points into high-growth international
healthcare markets, with a focus on Southeast Asia and the Middle East, where scalable
innovation is in high demand.
4. Joint Ventures with Specialized Clinics and Medical Institutions
BNCM and DELEX is actively structuring strategic partnerships with regional clinics and
hospital groups to roll out its digital health infrastructure, enhancing both access and
efficiency in patient care.
5. M&A Pipeline and Technology Acquisitions
BNCM and DELEX has identified several targets across the AI diagnostics, telehealth, and
medical device segments, with negotiations underway to strengthen its intellectual property
portfolio and expand service capabilities.
6. Investor and Stakeholder Engagement
As transparency and alignment remain top priorities, the Company is committed to
maintaining consistent communication with its shareholders, analysts, and institutional
partners throughout its growth trajectory.
Final Remarks
“We are immensely proud of the progress made in 2024, and even more excited about
what lies ahead in 2025,” said a BNCM spokesperson. “With DELEX’s leadership,
technology, and global vision, Bounce Mobile Systems is no longer just transitioning — we
are now executing on a bold mission to redefine access to innovative healthcare solutions.”
About Bounce Mobile Systems, Inc. (BNCM)

On July 2nd, 2024 press release, the Board of Directors of DELEX Healthcare Group Inc.
(DELEX) and Bounce Mobile Systems Inc. (BNCM) has signed an agreement for the
acquisition / merger between DELEX and BNCM. The Board of Directors of both DELEX
and BNCM plan to complete the required merger within the coming weeks.
About DELEX Healthcare Group, Inc. (DELEX)
DELEX is on a mission to revolutionize the pharmaceutical and healthcare industry. As a
Delaware-registered company, DELEX partnership with JMN Brothers Pharma Limited,
Inc. and DLX Holdings, Inc., brought high-quality products to market. With a focus on
innovation, regulatory excellence, and customer service, DELEX strives to meet the
growing demands of the market while adhering to the highest standard of regulatory
compliance and customer service excellence.
For more information, visit - https://bncm.net and https://bncm.us

[sissyjane1]

I stand corrected on fin statements ...pretty darn impressive what I like is no convt debt and the future itinerary for 2025
seems like Delex is going to be very very busy this year with a lot of things that will come to fruition which will lend to big revenue gains, I also like the 3.4 million dollar contract for a private hospital in Bulacan for imagining which they have received 500,000 down payment , new contracts with India and Chine for medical deals , 12 new pharmacy ,and attending medical conventions every month thru 11/25, plus introducing 12 new products for market, like I said busy busy ,busy DELEX STRONG.

[ToucanYoucan]

$BNCM - Financial Statements - You have to scroll down a bit
https://www.otcmarkets.com/otcapi/company/financial-report/454379/content

[sissyjane1]

seems like always a big dump at close ...640 k t trade

[sissyjane1]

who posted 150k for profits ...the fins have not dropped yet , i will remember to notify you when we hit 1.00 . delex has been around for 15 years I doubt its a scam ...we will see , heck all lawyers are crooks

[Hitman970]

Rudimentary analysis?
BNCM is a 100% proven scam.
Please provide ANY links to a news report (Not Twitter/ X and not company press) that counters the pump job BNCM as a successful company.
(Remember scams can register with governments, exchanges, and flaunt bogus filings.)
Vic D is their lawyer. Yawn.

[ToucanYoucan]

$BNCM - Thank you for your rudimentary analysis of the financial statements:

150,000 net profit on millions in revenue...

[Hitman970]

Toucan,
Thanks for your input.
I stand by my DD. This is a scam run by Vic D.
Please post any link from anywhere except Delex or BNCM to prove otherwise. NO mainstream media outlet has ever covered this POS. If it ever goes above 1$ I WILL NEVER POST ON IHUB AGAIN. Until then please GULP THE KOOL-AID.

[Hitman970]

150,000 net profit on millions in revenue...

[Penny Stocks 2.0]

Nice filing out 
Bounce Mobile Systems, Inc. (OTC: BNCM) Supplemental Filing Company Provides Strategic 2025 Forward Guidance & Outlook post-Merger with DELEX Healthcare Group April 2025 — Bounce Mobile Systems, Inc. (OTC: BNCM) (“BNCM” or the “Company”) is pleased to provide shareholders with a comprehensive supplemental OTC MARKETS filing update on its 2025 outlook, continuing the momentum set forth in its successful 2024 merger with DELEX Healthcare Group, Inc., and reinforcing its strategic evolution into a fully integrated healthcare innovation company. As outlined in our previously published PR updates, BNCM’s transition into the healthcare sector under the leadership of the DELEX Group has marked a transformative era for the Company. This transition has brought forward a dynamic management structure, access to proprietary technologies, and an ambitious roadmap to position BNCM as a disruptive player in the healthcare innovation ecosystem. 2024 Milestones Recap 1. Strategic Merger with DELEX Healthcare Group, Inc. This merger laid the foundation for the Company’s pivot into advanced healthcare solutions, leveraging DELEX’s operational infrastructure, industry expertise, and growing network of healthcare assets. 2. Management and Control Shift to DELEX Group As announced in Q1 2024, the shift in control to DELEX brought in a highly experienced executive team with a proven record in scaling healthcare ventures, enhancing corporate governance, and driving shareholder value. 3. Roadmap Unveiled for Innovation and Market Penetration BNCM and DELEX introduced a multi-phase plan to integrate digital health technologies, expand service offerings, and establish a footprint in emerging medical markets. 4. Operational Realignment and Asset Optimization Throughout 2024, BNCM and DELEX is focused on consolidating its legacy operations, reallocating resources toward scalable healthcare initiatives, and exploring synergistic acquisitions within the health-tech space. 2025 Strategic Outlook and Forward Plans Looking ahead, BNCM and DELEX is fully committed to accelerating the deployment of innovative healthcare solutions and expanding its market reach through: 1. Delivering Continued Growth DELEX has posted strong growth for the past 15 years and now has over 200 staffs, 30 Products approved by the Philippines FDA, supplies to over 900 pharmacies and hospitals, 160 drug chains and over 380 dispensing medical doctors and clinics. DELEX will continue to develop in-demand high quality products, secure more innovative medical technologies, expand its distribution channels, formed strategic partnerships across the region, increase its pharmacy stores from 3 to 60 and actively participate in medical conventions and exhibitions.2. Delivering Innovative and Cutting-Edge Medical Technologies DELEX has introduced various advanced technologies, starting with the CADD-Solis infusion systems from Smiths Medical, Ultrasound for Cardiology from Philips, Neutraclear needleless connectors from CAIR LGL. Anesthesia Unit, Electrosurgical Unit, Surgical light, and Surgical table from SternMed GmbH. 3. International Expansion Strategy BNCM and DELEX are jointly evaluating entry points into high-growth international healthcare markets, with a focus on Southeast Asia and the Middle East, where scalable innovation is in high demand. 4. Joint Ventures with Specialized Clinics and Medical Institutions BNCM and DELEX is actively structuring strategic partnerships with regional clinics and hospital groups to roll out its digital health infrastructure, enhancing both access and efficiency in patient care. 5. M&A Pipeline and Technology Acquisitions BNCM and DELEX has identified several targets across the AI diagnostics, telehealth, and medical device segments, with negotiations underway to strengthen its intellectual property portfolio and expand service capabilities. 6. Investor and Stakeholder Engagement As transparency and alignment remain top priorities, the Company is committed to maintaining consistent communication with its shareholders, analysts, and institutional partners throughout its growth trajectory. Final Remarks “We are immensely proud of the progress made in 2024, and even more excited about what lies ahead in 2025,” said a BNCM spokesperson. “With DELEX’s leadership, technology, and global vision, Bounce Mobile Systems is no longer just transitioning — we are now executing on a bold mission to redefine access to innovative healthcare solutions.” About Bounce Mobile Systems, Inc. (BNCM) On July 2nd, 2024 press release, the Board of Directors of DELEX Healthcare Group Inc. (DELEX) and Bounce Mobile Systems Inc. (BNCM) has signed an agreement for the acquisition / merger between DELEX and BNCM. The Board of Directors of both DELEX and BNCM plan to complete the required merger within the coming weeks. About DELEX Healthcare Group, Inc. (DELEX) DELEX is on a mission to revolutionize the pharmaceutical and healthcare industry. As a Delaware-registered company, DELEX partnership with JMN Brothers Pharma Limited, Inc. and DLX Holdings, Inc., brought high-quality products to market. With a focus on innovation, regulatory excellence, and customer service, DELEX strives to meet the growing demands of the market while adhering to the highest standard of regulatory compliance and customer service excellence. For more information, visit - https://bncm.net and https://bncm.us

[MrYoung]

$BNCM is up now.

[sissyjane1]

I am with you Humbert , hoping for great fin news

[Humbert]

Don't worry, it'll come. Few realize the opportunity here

[sissyjane1]

all great news but ready for the fins to drop . all this news is regurgitation of past posted news , exciting future ahead
go Delex.

[Humbert]

Audited financials should drop soon, followed by an uplist - it's a once in a lifetime opportunity.